Results 171 to 180 of about 3,598,260 (304)

A Catalogue of Dispensation Lengths for Building Treatment Episodes-Application of the Waiting Time Distribution to All Commonly Prescribed Drugs in Denmark. [PDF]

Pharmacoepidemiol Drug Saf
Reilev M, Rasmussen L, Olsen JK, Ernst MT, Abbasi SH, Wesselhoeft R, Bliddal M, Hallas J, Støvring H.   +8 more
europepmc   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Correction: Impact of Aspirin on Primary Prevention of Cardiovascular Events in Patients with Elevated Lipoprotein(a): A Systematic Review and Meta-analysis. [PDF]

Am J Cardiovasc Drugs
Caldeira D, Alves M, Avó-Baião R, Lopes A, Prada L, Pinto FJ.   +5 more
europepmc   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Drugs, Market Size and Population [PDF]

This paper addresses the upward trend in new drugs introduced by pharmaceutical firms, during the second half of the 20th century. We indicate that the continuous increases in population, and thus in the market size of this sector, will play a ...
Rodrigo Cerda
core  

Exceptional treatment responses and molecular markers among 103 colorectal cancer cell lines. [PDF]

Mol Biomed
Sveen A, Stenersen JM, Asenso TQ, Klokkerud SK, Kranjec C, Eilertsen IA, Johannessen B, Leithe E, Kryeziu K, Zucknick M, Lothe RA.   +10 more
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Drugs of abuse.

, 1970
Description based on: 1985.Cover title.Mode of access: Internet.Issued by: U.S. Bureau of Narcotics and Dangerous Drugs, 1970-1972; U.S. Dept.
United States. Bureau of Narcotics and Dangerous Drugs., United States. Drug Enforcement Administration.   +1 more
core  

Disproportionality analysis of drug-induced myocarditis: Insights from the Food and Drug Administration Adverse Event Reporting System database. [PDF]

J Int Med Res
Pang J, Zhu W, Zhang Y, Guo W.
europepmc   +1 more source